These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 36649392)

  • 21. [Empagliflozin in the elderly].
    Berrut G; Boureau AS; Trochu JN; Genet B; de Decker L; Hanon O
    Geriatr Psychol Neuropsychiatr Vieil; 2021 Jun; 19(2):137-147. PubMed ID: 34165436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus.
    Jordan J; Tank J; Heusser K; Heise T; Wanner C; Heer M; Macha S; Mattheus M; Lund SS; Woerle HJ; Broedl UC
    J Am Soc Hypertens; 2017 Sep; 11(9):604-612. PubMed ID: 28757109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes.
    Peacock SC; Lovshin JA; Cherney DZI
    Anesth Analg; 2018 Feb; 126(2):699-704. PubMed ID: 28786838
    [No Abstract]   [Full Text] [Related]  

  • 24. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
    Shin Y; Moon JH; Chin HJ; Ferrannini E; Lim S
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart.
    Santulli G; Varzideh F; Forzano I; Wilson S; Salemme L; de Donato A; Lombardi A; Rainone A; Nunziata L; Jankauskas SS; Tesorio T; Guerra G; Kansakar U; Mone P
    Hypertension; 2023 Sep; 80(9):1800-1809. PubMed ID: 37403685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 1 Diabetes Mellitus.
    Li N; Chen R; Liu K
    Clin Drug Investig; 2020 Nov; 40(11):991-1000. PubMed ID: 32725362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weight Outcomes With Empagliflozin as Compared With Liraglutide in Veterans With Type 2 Diabetes Mellitus.
    Grabarczyk TR; Wissman NK
    Ann Pharmacother; 2020 Oct; 54(10):981-987. PubMed ID: 32274930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.
    Lamos EM; Younk LM; Davis SN
    Expert Opin Investig Drugs; 2014 Jun; 23(6):875-82. PubMed ID: 24746173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RNA-Seq transcriptomic landscape profiling of spontaneously hypertensive rats treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor.
    Tan F; Long X; Du J; Yuan X
    Biomed Pharmacother; 2023 Oct; 166():115289. PubMed ID: 37572641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced Mortality With Sodium-Glucose Cotransporter-2 Inhibitors in Observational Studies: Avoiding Immortal Time Bias.
    Suissa S
    Circulation; 2018 Apr; 137(14):1432-1434. PubMed ID: 29610125
    [No Abstract]   [Full Text] [Related]  

  • 31. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.
    Lai LL; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    Dig Dis Sci; 2020 Feb; 65(2):623-631. PubMed ID: 30684076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling.
    Sokolov V; Yakovleva T; Chu L; Tang W; Greasley PJ; Johansson S; Peskov K; Helmlinger G; Boulton DW; Penland RC
    CPT Pharmacometrics Syst Pharmacol; 2020 Apr; 9(4):222-229. PubMed ID: 32064793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
    Gonzalez DE; Foresto RD; Ribeiro AB
    Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
    Yaribeygi H; Maleki M; Sathyapalan T; Jamialahmadi T; Sahebkar A
    Curr Med Chem; 2023; 30(25):2850-2863. PubMed ID: 36045524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.
    Zhao X; Cui Y; Zhao S; Lang B; Broedl UC; Salsali A; Pinnetti S; Macha S
    Clin Ther; 2015 Jul; 37(7):1493-502. PubMed ID: 26101175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes.
    Hussain M; Elahi A; Hussain A; Iqbal J; Akhtar L; Majid A
    J Diabetes Res; 2021; 2021():9973862. PubMed ID: 34239940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of SGLT2 inhibitors in managing type 2 diabetes.
    Tat V; Forest CP
    JAAPA; 2018 Jun; 31(6):35-40. PubMed ID: 29846314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME].
    Scheen AJ
    Rev Med Liege; 2019 Apr; 74(4):185-191. PubMed ID: 30997967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.
    Sattar N; Fitchett D; Hantel S; George JT; Zinman B
    Diabetologia; 2018 Oct; 61(10):2155-2163. PubMed ID: 30066148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.